Crossmark

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Crossref DOI link: https://doi.org/10.1136/jitc-2022-004656

Published Online: 2022-04-03

Published Print: 2022-04

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Xia, Yongxiang

Tang, Weiwei https://orcid.org/0000-0002-8516-819X
Qian, Xiaofeng

Li, Xiangcheng

Cheng, Feng

Wang, Ke

Zhang, Feng

Zhang, Chuanyong

Li, Donghua

Song, Jinhua

Zhang, Hui

Zhao, Jie

Yao, Aihua

Wu, Xiaofeng

Wu, Chen

Ji, Guwei https://orcid.org/0000-0003-1736-062X
Liu, Xisheng

Zhu, Feipeng

Qin, Lang

Xiao, Xuan

Deng, Zhenhua

Kong, Xiangyi

Li, Si

Yu, Yangyang

Xi, Wenjing

Deng, Wanglong

Qi, Chuang

Liu, Hanyuan

Pu, Liyong

Wang, Ping

Wang, Xuehao
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04297202 at ClinicalTrials.gov

Documents that mention this clinical trial

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
https://doi.org/10.1136/jitc-2022-004656
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82070676)

National Natural Science Key Foundation of China (31930020)
License Information

License valid from 2022-04-01

Document is current

Any future updates will be listed below